Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects</title><author><name sortKey="Michalakis, Konstantinos" sort="Michalakis, Konstantinos" uniqKey="Michalakis K" first="Konstantinos" last="Michalakis">Konstantinos Michalakis</name><affiliation><nlm:aff id="aff1">Private Practice, 10-12 Dorylaiou Str, Athens, GR11521, Greece</nlm:aff></affiliation></author><author><name sortKey="Ilias, Ioannis" sort="Ilias, Ioannis" uniqKey="Ilias I" first="Ioannis" last="Ilias">Ioannis Ilias</name><affiliation><nlm:aff id="aff2">Department of Endocrinology, Diabetes & Metabolism, Elena Venizelou Hospital, 2 Elena Venizelou Sq, Athens, GR11521, Greece</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">7189186</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189186</idno><idno type="RBID">PMC:7189186</idno><idno type="doi">10.1016/j.dsx.2020.04.033</idno><idno type="pmid">NONE</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000641</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000641</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects</title><author><name sortKey="Michalakis, Konstantinos" sort="Michalakis, Konstantinos" uniqKey="Michalakis K" first="Konstantinos" last="Michalakis">Konstantinos Michalakis</name><affiliation><nlm:aff id="aff1">Private Practice, 10-12 Dorylaiou Str, Athens, GR11521, Greece</nlm:aff></affiliation></author><author><name sortKey="Ilias, Ioannis" sort="Ilias, Ioannis" uniqKey="Ilias I" first="Ioannis" last="Ilias">Ioannis Ilias</name><affiliation><nlm:aff id="aff2">Department of Endocrinology, Diabetes & Metabolism, Elena Venizelou Hospital, 2 Elena Venizelou Sq, Athens, GR11521, Greece</nlm:aff></affiliation></author></analytic><series><title level="j">Diabetes & Metabolic Syndrome</title><idno type="ISSN">1871-4021</idno><idno type="eISSN">1878-0334</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Backround and aims</title><p>According to the World Obesity Federation, “obesity-related conditions seem to worsen the effect of Covid-19 (SARS-CoV-2)”; additionally the Centres for Disease Control and Prevention reported that “people with heart disease and diabetes are at higher risk of SARS-CoV-2 complications and that severe obesity poses a higher risk for severe illness”. Recent reports have shown elevated levels of cytokines due to increased inflammation in patients with SARS-CoV-2 disease. On the other hand, obesity represents a state of low-grade inflammation, with various inflammatory products directly excreted by adipose tissue. In this concise report we aimed to assess common elements of obesity and SARS-CoV-2 infection.</p></sec><sec><title>Methods</title><p>Literature search on obesity and SARS-CoV-2 infection.</p></sec><sec><title>Results</title><p>We present “mechanistic” obesity-related problems that aggravate SARS-CoV-2 infection as well as tentative inflammatory/metabolic links between these diseases.</p></sec><sec><title>Conclusion</title><p>Obesity and SARS-CoV-2 share common elements of the inflammatory process (and possibly also metabolic disturbances), exacerbating SARS-CoV-2 infection in the obese.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="World Health Organisation Who" uniqKey="World Health Organisation Who">World Health Organisation (WHO)</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="World Health Organisation Who" uniqKey="World Health Organisation Who">World Health Organisation (WHO)</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Michalakis, K" uniqKey="Michalakis K">K. Michalakis</name></author><author><name sortKey="Goulis, D G" uniqKey="Goulis D">D.G. Goulis</name></author><author><name sortKey="Vazaiou, A" uniqKey="Vazaiou A">A. Vazaiou</name></author><author><name sortKey="Mintziori, G" uniqKey="Mintziori G">G. Mintziori</name></author><author><name sortKey="Polymeris, A" uniqKey="Polymeris A">A. Polymeris</name></author><author><name sortKey="Abrahamian Michalakis, A" uniqKey="Abrahamian Michalakis A">A. Abrahamian-Michalakis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Centres For Disease Control And Prevention Cdc" uniqKey="Centres For Disease Control And Prevention Cdc">Centres for Disease Control and Prevention (CDC)</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sun, Y" uniqKey="Sun Y">Y. Sun</name></author><author><name sortKey="Wang, Q" uniqKey="Wang Q">Q. Wang</name></author><author><name sortKey="Yang, G" uniqKey="Yang G">G. Yang</name></author><author><name sortKey="Lin, C" uniqKey="Lin C">C. Lin</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y. Zhang</name></author><author><name sortKey="Yang, P" uniqKey="Yang P">P. Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Neidich, S D" uniqKey="Neidich S">S.D. Neidich</name></author><author><name sortKey="Green, W D" uniqKey="Green W">W.D. Green</name></author><author><name sortKey="Rebeles, J" uniqKey="Rebeles J">J. Rebeles</name></author><author><name sortKey="Karlsson, E A" uniqKey="Karlsson E">E.A. Karlsson</name></author><author><name sortKey="Schultz Cherry, S" uniqKey="Schultz Cherry S">S. Schultz-Cherry</name></author><author><name sortKey="Noah, T L" uniqKey="Noah T">T.L. Noah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ryan, D H" uniqKey="Ryan D">D.H. Ryan</name></author><author><name sortKey="Ravussin, E" uniqKey="Ravussin E">E. Ravussin</name></author><author><name sortKey="Heymsfield, S" uniqKey="Heymsfield S">S. Heymsfield</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, N" uniqKey="Chen N">N. Chen</name></author><author><name sortKey="Zhou, M" uniqKey="Zhou M">M. Zhou</name></author><author><name sortKey="Dong, X" uniqKey="Dong X">X. Dong</name></author><author><name sortKey="Qu, J" uniqKey="Qu J">J. Qu</name></author><author><name sortKey="Gong, F" uniqKey="Gong F">F. Gong</name></author><author><name sortKey="Han, Y" uniqKey="Han Y">Y. Han</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ilias, I" uniqKey="Ilias I">I. Ilias</name></author><author><name sortKey="Zabuliene, L" uniqKey="Zabuliene L">L. Zabuliene</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, X" uniqKey="Zhang X">X. Zhang</name></author><author><name sortKey="Wu, K" uniqKey="Wu K">K. Wu</name></author><author><name sortKey="Wang, D" uniqKey="Wang D">D. Wang</name></author><author><name sortKey="Yue, X" uniqKey="Yue X">X. Yue</name></author><author><name sortKey="Song, D" uniqKey="Song D">D. Song</name></author><author><name sortKey="Zhu, Y" uniqKey="Zhu Y">Y. Zhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fang, X" uniqKey="Fang X">X. Fang</name></author><author><name sortKey="Gao, J" uniqKey="Gao J">J. Gao</name></author><author><name sortKey="Zheng, H" uniqKey="Zheng H">H. Zheng</name></author><author><name sortKey="Li, B" uniqKey="Li B">B. Li</name></author><author><name sortKey="Kong, L" uniqKey="Kong L">L. Kong</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y. Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Canton, J" uniqKey="Canton J">J. Canton</name></author><author><name sortKey="Fehr, A R" uniqKey="Fehr A">A.R. Fehr</name></author><author><name sortKey="Fernandez Delgado, R" uniqKey="Fernandez Delgado R">R. Fernandez-Delgado</name></author><author><name sortKey="Gutierrez Alvarez, F J" uniqKey="Gutierrez Alvarez F">F.J. Gutierrez-Alvarez</name></author><author><name sortKey="Sanchez Aparicio, M T" uniqKey="Sanchez Aparicio M">M.T. Sanchez-Aparicio</name></author><author><name sortKey="Garcia Sastre, A" uniqKey="Garcia Sastre A">A. García-Sastre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ulhaq, Z S" uniqKey="Ulhaq Z">Z.S. Ulhaq</name></author><author><name sortKey="Soraya, G V" uniqKey="Soraya G">G.V. Soraya</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huang, C" uniqKey="Huang C">C. Huang</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y. Wang</name></author><author><name sortKey="Li, X" uniqKey="Li X">X. Li</name></author><author><name sortKey="Ren, L" uniqKey="Ren L">L. Ren</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J. Zhao</name></author><author><name sortKey="Hu, Y" uniqKey="Hu Y">Y. Hu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Divella, R" uniqKey="Divella R">R. Divella</name></author><author><name sortKey="De Luca, R" uniqKey="De Luca R">R. De Luca</name></author><author><name sortKey="Abbate, I" uniqKey="Abbate I">I. Abbate</name></author><author><name sortKey="Naglieri, E" uniqKey="Naglieri E">E. Naglieri</name></author><author><name sortKey="Daniele, A" uniqKey="Daniele A">A. Daniele</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Michalakis, K" uniqKey="Michalakis K">K. Michalakis</name></author><author><name sortKey="Venihaki, M" uniqKey="Venihaki M">M. Venihaki</name></author><author><name sortKey="Mantzoros, C" uniqKey="Mantzoros C">C. Mantzoros</name></author><author><name sortKey="Vazaiou, A" uniqKey="Vazaiou A">A. Vazaiou</name></author><author><name sortKey="Ilias, I" uniqKey="Ilias I">I. Ilias</name></author><author><name sortKey="Gryparis, A" uniqKey="Gryparis A">A. Gryparis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ellulu, M S" uniqKey="Ellulu M">M.S. Ellulu</name></author><author><name sortKey="Patimah, I" uniqKey="Patimah I">I. Patimah</name></author><author><name sortKey="Khaza Ai, H" uniqKey="Khaza Ai H">H. Khaza'ai</name></author><author><name sortKey="Rahmat, A" uniqKey="Rahmat A">A. Rahmat</name></author><author><name sortKey="Abed, Y" uniqKey="Abed Y">Y. Abed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stone, T W" uniqKey="Stone T">T.W. Stone</name></author><author><name sortKey="Mcpherson, M" uniqKey="Mcpherson M">M. McPherson</name></author><author><name sortKey="Gail Darlington, L" uniqKey="Gail Darlington L">L. Gail Darlington</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, A J" uniqKey="Zhang A">A.J. Zhang</name></author><author><name sortKey="To, K K" uniqKey="To K">K.K. To</name></author><author><name sortKey="Li, C" uniqKey="Li C">C. Li</name></author><author><name sortKey="Lau, C C" uniqKey="Lau C">C.C. Lau</name></author><author><name sortKey="Poon, V K" uniqKey="Poon V">V.K. Poon</name></author><author><name sortKey="Chan, C C" uniqKey="Chan C">C.C. Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lelis, D F" uniqKey="Lelis D">D.F. Lelis</name></author><author><name sortKey="Freitas, D F" uniqKey="Freitas D">D.F. Freitas</name></author><author><name sortKey="Machado, A S" uniqKey="Machado A">A.S. Machado</name></author><author><name sortKey="Crespo, T S" uniqKey="Crespo T">T.S. Crespo</name></author><author><name sortKey="Santos, S H S" uniqKey="Santos S">S.H.S. Santos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Danser, A H J" uniqKey="Danser A">A.H.J. Danser</name></author><author><name sortKey="Epstein, M" uniqKey="Epstein M">M. Epstein</name></author><author><name sortKey="Batlle, D" uniqKey="Batlle D">D. Batlle</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Metab Syndr</journal-id><journal-title-group><journal-title>Diabetes & Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="ppub">1871-4021</issn><issn pub-type="epub">1878-0334</issn><publisher><publisher-name>Published by Elsevier Ltd on behalf of Diabetes India.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">7189186</article-id><article-id pub-id-type="publisher-id">S1871-4021(20)30098-9</article-id><article-id pub-id-type="doi">10.1016/j.dsx.2020.04.033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Michalakis</surname><given-names>Konstantinos</given-names></name><email>kostismichalakis@hotmail.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Ilias</surname><given-names>Ioannis</given-names></name><email>iiliasmd@yahoo.com</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">∗</xref></contrib><aff id="aff1"><label>a</label>Private Practice, 10-12 Dorylaiou Str, Athens, GR11521, Greece</aff><aff id="aff2"><label>b</label>Department of Endocrinology, Diabetes & Metabolism, Elena Venizelou Hospital, 2 Elena Venizelou Sq, Athens, GR11521, Greece</aff></contrib-group><author-notes><corresp id="cor1"><label>∗</label>Corresponding author. <email>iiliasmd@yahoo.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>29</day><month>4</month><year>2020</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="epub"><day>29</day><month>4</month><year>2020</year></pub-date><history><date date-type="received"><day>13</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>22</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>© 2020 Published by Elsevier Ltd on behalf of Diabetes India.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder></copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><sec><title>Backround and aims</title><p>According to the World Obesity Federation, “obesity-related conditions seem to worsen the effect of Covid-19 (SARS-CoV-2)”; additionally the Centres for Disease Control and Prevention reported that “people with heart disease and diabetes are at higher risk of SARS-CoV-2 complications and that severe obesity poses a higher risk for severe illness”. Recent reports have shown elevated levels of cytokines due to increased inflammation in patients with SARS-CoV-2 disease. On the other hand, obesity represents a state of low-grade inflammation, with various inflammatory products directly excreted by adipose tissue. In this concise report we aimed to assess common elements of obesity and SARS-CoV-2 infection.</p></sec><sec><title>Methods</title><p>Literature search on obesity and SARS-CoV-2 infection.</p></sec><sec><title>Results</title><p>We present “mechanistic” obesity-related problems that aggravate SARS-CoV-2 infection as well as tentative inflammatory/metabolic links between these diseases.</p></sec><sec><title>Conclusion</title><p>Obesity and SARS-CoV-2 share common elements of the inflammatory process (and possibly also metabolic disturbances), exacerbating SARS-CoV-2 infection in the obese.</p></sec></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>•</label><p id="p0010">Obesity is associated with low-grade inflammation and insulin resistance.</p></list-item><list-item id="u0015"><label>•</label><p id="p0015">SARS-CoV-2 infection triggers an inflammatory cascade and may cause hyperglycemia.</p></list-item><list-item id="u0020"><label>•</label><p id="p0020">Both diseases share some common inflammatory (and possibly also metabolic) pathways; this may explain why the obese are more vulnerable to SARS-CoV-2 infection.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Human</kwd><kwd>Coronavirus</kwd><kwd>Obesity</kwd><kwd>Glucose</kwd><kwd>Inflammation</kwd><kwd>Infection</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0025">Physicians are trying to establish the risk factors that might affect the spread of the novel SARS-CoV-2 virus and those that might worsen the prognosis of hospitalised patients [<xref rid="bib1" ref-type="bibr">1</xref>]. Among those, it seems that the new pandemic is complicated by an older one, which is already well-defined, that is obesity. Being overweight and obesity are defined as having abnormal or excessive fat accumulation, respectively, that may impair health [<xref rid="bib2" ref-type="bibr">2</xref>]. Obesity has nearly tripled worldwide since 1975, hence it has been characterised as a pandemic. In 2016, 39% of adults worldwide (more than 1.9 billion people) were overweight and 13% were obese (over 650 million people), whereas in 2018, 40 million children under the age of 5 were overweight or obese. Obesity is a major health concern, mainly because of its side-effects in humans and its associated morbidity and mortality rates [<xref rid="bib3" ref-type="bibr">3</xref>].</p><p id="p0030">On the other hand, according to the World Obesity Federation, obesity-related conditions seem to worsen the effect of SARS-CoV-2; indeed, the Centres for Disease Control and Prevention (CDC) reported that “people with heart disease and diabetes are at higher risk of Covid-19 (SARS-CoV-2) complications and that severe obesity (body mass index [BMI] of 40 or higher) poses a higher risk for severe illness” [<xref rid="bib4" ref-type="bibr">4</xref>].</p><p id="p0035">We therefore hypothesised that there might be a pathophysiological link that could explain the fact that obese patients are prone to present with SARS-CoV-2 complications.</p><p id="p0040">Looking back on similar infectious outbreaks, during the 2009 H1N1 pandemic, obesity was recognized as an independent risk factor for complications from influenza [<xref rid="bib5" ref-type="bibr">5</xref>], thus it is not surprising that obesity is a potential independent risk factor for SARS-CoV-2 as well. Obese individuals have shown diminished protection from influenza immunization, since - despite being vaccinated - obese recipients are 2–3 times more prone to suffer from infection compared to non-obese. Thus, the potential implications for obesity in the SARS-CoV-2 outbreak should be elucidated [<xref rid="bib6" ref-type="bibr">6</xref>]. We hereby present “mechanistic” obesity-related problems that aggravate SARS-CoV-2 infection as well as tentative molecular links between obesity and SARS-CoV-2 infection.</p></sec><sec id="sec2"><label>2</label><title>“Mechanistic” problems</title><p id="p0045">Obese patients often need bariatric hospital beds, which may be scarce and are definitely more difficult to position and transport by nursing staff. In these patients proper imaging diagnosis may be compromised (there are weight limits for the beds of imaging equipment). Obese patients are very prone to diminished airway flow, due to limited truncal expansion, making it difficult to ease the airflow (and increasing susceptibility to poor breathing) [<xref rid="bib7" ref-type="bibr">7</xref>]; oxygen consumption and respiratory potential can be seriously affected and predispose to infection and the need for more oxygen support [<xref rid="bib7" ref-type="bibr">7</xref>]. Finally these patients pose a serious challenge for intubation (since the additional adipose tissue on the larynx makes intubation more difficult).</p></sec><sec id="sec3"><label>3</label><title>Molecular pathways</title><p id="p0050">So far, hyperglycemia was noted in 51% of cases with the novel SARS-CoV-2 infection [<xref rid="bib8" ref-type="bibr">8</xref>]. Hyperglycemia was also observed in patients with SARS in 2003, caused by a different type of coronavirus (SARS-CoV), partly because the virus leads to transient impairment of pancreatic islet cell function [<xref rid="bib9" ref-type="bibr">9</xref>]. Dipeptidyl peptidase 4 (DPP4; an enzyme responsible for the degradation of incretins such as glucagon like peptide-1, GLP-1) serves as receptor for MERS CoV (Middle eastern respiratory syndrome) and human coronavirus EMC [<xref rid="bib9" ref-type="bibr">9</xref>]. Moreover, hyperglycemia might also be caused by endogenous stress-induced glucocorticoid hypersecretion [<xref rid="bib9" ref-type="bibr">9</xref>].</p><p id="p0055">Recent reports have shown an increased inflammatory environment, leading to a exacerbated cytokine profile (cytokine storm) in patients with SARS-CoV-2 disease [<xref rid="bib10" ref-type="bibr">10</xref>], mainly manifested by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemo-attractant protein 1 (MCP1), macrophage inflammatory protein 1-α, and tumour necrosis factor-α (TNFα). Earlier investigations of SARS-CoV infection, showed that it mediated its actions via suppression of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity, resulting in lower Cox-2 (cyclooxygenase-2) expression (thus easing inflammation) [<xref rid="bib11" ref-type="bibr">11</xref>]. In MERS-CoV infection, translocation of NF-κB to the nucleus leads to a cascade of pro-inflammatory cytokines [<xref rid="bib12" ref-type="bibr">12</xref>]. Among all interleukins, IL-6 was found to be associated with a highly pathogenic SARS-CoV-2 infection, due to enhanced virus replication mainly in the lower respiratory tract [<xref rid="bib13" ref-type="bibr">13</xref>]. Moreover, levels of ferritin and IL-6 were statistically significantly higher in non-survivors compared to survivors in the recent outbreak of SARS-CoV-2 in China [<xref rid="bib14" ref-type="bibr">14</xref>].</p><p id="p0060">Obesity represents a state of low-grade inflammation, with various inflammatory products directly secreted by adipose tissue. Hyperplastic or hypertrophied adipose tissue releases inflammatory cytokines (TNFα, IL-1, IL-6, IL-10), transforming growth factor-b (TGF-b), adipokines (leptin, resistin, adiponectin), MCP-1 (monocyte chemoattractant protein-1), CXCL5 (C-X-C motif chemokine ligand 5), hemostatic proteins (plasminogen activator inhibitor-1; PAI-1), proteins affecting blood pressure, (angiotensinogen) and angiogenic molecules (vascular endothelial growth factor; VEGF) [<xref rid="bib15" ref-type="bibr">15</xref>]. The main adipose tissue-derived inflammatory cytokines are TNFα, IL-1, IL-6, which altogether comprise an “inflammatory triad”. Levels of TNFα are increased in obesity, indicating a role for this cytokine in the obesity-associated inflammation and particularly in insulin resistance and diabetes. Interleukin-1 can lead to the activation of transcription factors such as NF-kB, promoting inflammatory signalling overexpression of the angiogenic factor VEGF (vascular endothelial growth factor), while increased levels of IL-6 in obesity play a key role in inflammation-associated carcinogenesis, via the JAK/STAT (Janus kinase signal transducer and activator of transcription) signalling pathway [<xref rid="bib16" ref-type="bibr">16</xref>]. Features of inflammation are consequent hypoxia and ischemia (hypoxia is the lack of oxygen in the blood or in adipose tissue, while ischemia is caused by an inadequate blood flow). Both hypoxia and ischemia drive to a state of oxidative stress, further stimulating the secretion of inflammatory proteins and reactive oxygen radicals (radical oxygen species, ROS) that damage mitochondrial functionality and DNA [<xref rid="bib17" ref-type="bibr">17</xref>]. Thus, the hypertrophic, and at the same time hypoxic, white adipocytes change their normal protein synthesis and shift towards the production of cytokines and inflammatory proteins, leading to insulin resistance, type 2 diabetes mellitus (T2DM), metabolic syndrome, atherosclerosis and arterial hypertension, while recent evidence favours their implication in various types of cancer [<xref rid="bib18" ref-type="bibr">18</xref>].</p><p id="p0065">Among the various products of adipose tissue, is leptin. Leptin is a cytokine that serves as an alarm (inhibition signal) to the body, in order to reduce caloric consumption and return to a steady state. Initially thought as the cure for obesity in a recombinant form, leptin was found to face serious resistance in the body of the obese. Although in obesity leptin levels are increased, the action of leptin <italic>per se</italic> is reduced, in a analogous way to insulin's action in patients with T2DM. Zhang et al. suggested that leptin resistance could aggravate the outcome of the patients during the 2009 A (H1N1) pandemic influenza, since leptin exerts positive effects in B cell maturation, development and function, along with alterations of lymphocytes and inhibition of CD8<sup>+</sup> T cell response and impaired memory T cell response, seen in obesity, which both under normal circumstances would act against the virus [<xref rid="bib19" ref-type="bibr">19</xref>].</p><p id="p0070">Hyperglycaemia or established T2DM (usually associated with obesity) have shown to be independent predictors of mortality and morbidity in patients with SARS [<xref rid="bib9" ref-type="bibr">9</xref>]. A proposed mechanism is that in SARS the noted enhanced release of cytokines leads to a state of increased metabolic inflammation. Especially in the case of SARS-CoV-2, a cytokine storm (elevated levels of inflammatory cytokines) has been suggested to be implicated in the multi-organ failure in patients with severe disease.</p><p id="p0075">Adipose tissue expresses most of the components of the renin angiotensin aldosterone system (RAAS), such as angiotensinogen (AGT), angiotensin converting enzymes (ACE and ACE2) and their receptors, their mRNA being reduced in starvation and increased in overfeeding. Angiotensin (AT) II promotes prostacyclin synthesis, differentiation of the adipocytes and lipogenesis. Inside the adipose cell, ACE is stimulated towards the conversion of angiotensin I to angiotensin II, thus further stimulating the RAAS axis, the production of aldosterone and the rise in blood pressure [<xref rid="bib20" ref-type="bibr">20</xref>]. Various reports have included arterial hypertension as a risk factor for severity of SARS-CoV-2, possibly related to ACE2 via the actions of ACE-inhibitors and AT receptor blockers (ARB), given for the treatment of hypertension (ACE2 acts as receptor that indeed seems to facilitate the entry of coronavirus into cells) [<xref rid="bib21" ref-type="bibr">21</xref>]. Of note, the percentage of patients with hypertension suffering from SARS-CoV-2 is roughly the same as the prevalence of hypertension in the same age group, regardless of SARS-CoV-2 infection, which means that hypetension is not a risk factor <italic>per se</italic>, but rather a pre-existing disease at that age group [<xref rid="bib21" ref-type="bibr">21</xref>]. Overall data do not fully support the notion that discontinuation of these medications is beneficial, since other reports in animals show that elevated ACE2 expression might exert potentially protective pulmonary and cardiovascular effects [<xref rid="bib21" ref-type="bibr">21</xref>] (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).<fig id="fig1"><label>Fig. 1</label><caption><p>Selected metabolic pathways for obesity and SARS-CoV-2 infection; their common elements are shown in grey boxes. In obesity, resistance to leptin (along with resistin) leads to insulin resistance (both in the brain and in peripheral tissues) and eventually to hyperglycemia and T2DM. Moreover, adipose tissue releases ATG, which, via ACE is converted to AT II and increases blood pressure. SARS-CoV-2 attaches to cells via ACE2 and may provoke hyperglycemia (see text for more details); <italic>FFA: free fatty acids, ATG: angiotensinogen, ACE: angiotensin converting enzyme, AT II: angiotensin II, AT 1–7: angiotensin 1-7 (vasodilatory), NO: Nitric Oxide, T2DM: type 2 diabetes mellitus, ACE2: angiotensin converting enzyme 2, *: is usually upregulated in subjects with hypertension on ACE-inhibitors and AT receptor blockers (ARB), **hyperglycemia has been reported in patients with SARS-CoV-2 infection – the specific mechanisms have not been elucidated</italic>.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"></graphic></fig></p><p id="p0080">Among the limitations of this work we have to note that although we presented possible and plausible links among the inflammatory and metabolic aspects of obesity and SARS-CoV-2 infection (based on the available - and rapidly evolving - literature), further relevant research is warranted.</p></sec><sec id="sec4"><label>4</label><title>Conclusion</title><p id="p0085">Both SARS-CoV-2 infection and obesity seem to share some common metabolic and inflammatory reaction pathways. On the one hand, obesity causes hyperglycemia via insulin resistance whereas SARS-CoV-2 may cause hyperglycemia as well (via mechanisms that are not elucidated yet). On the other hand, obesity represents a state of low grade inflammation, sharing many common molecules and pathways with those observed in SARS-CoV-2 infection.</p></sec><sec id="sec5"><title>Authors’ contributions</title><p id="p0090">Both KM and II conceived the idea for this review, searched the available literature and wrote the draft and final form of this article.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0095">The authors do not have any conflicts of interest and sources of funding to declare.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="other" id="sref1"><person-group person-group-type="author"><name><surname>World Health Organisation (WHO)</surname></name></person-group><article-title>Coronavirus disease (Covid-19) pandemic</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019" id="intref0010">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="other" id="sref2"><person-group person-group-type="author"><name><surname>World Health Organisation (WHO)</surname></name></person-group><article-title>Obesity</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/topics/obesity/en/" id="intref0015">https://www.who.int/topics/obesity/en/</ext-link></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Michalakis</surname><given-names>K.</given-names></name><name><surname>Goulis</surname><given-names>D.G.</given-names></name><name><surname>Vazaiou</surname><given-names>A.</given-names></name><name><surname>Mintziori</surname><given-names>G.</given-names></name><name><surname>Polymeris</surname><given-names>A.</given-names></name><name><surname>Abrahamian-Michalakis</surname><given-names>A.</given-names></name></person-group><article-title>Obesity in the ageing man</article-title><source>Metabolism</source><volume>62</volume><year>2013</year><fpage>1341</fpage><lpage>1349</lpage><pub-id pub-id-type="pmid">23831443</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="other" id="sref4"><person-group person-group-type="author"><name><surname>Centres for Disease Control and Prevention (CDC)</surname></name></person-group><article-title>Coronavirus (Covid-19)</article-title><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus" id="intref0020">https://www.cdc.gov/coronavirus</ext-link></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Lin</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name></person-group><article-title>Weight and prognosis for influenza A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: a systematic review of observational studies with meta-analysis</article-title><source>Inf Disp</source><volume>48</volume><issue>11–12</issue><year>2016 Nov-Dec</year><fpage>813</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1080/23744235.2016.1201721</pub-id><comment>Epub 2016 Jul 6</comment></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Neidich</surname><given-names>S.D.</given-names></name><name><surname>Green</surname><given-names>W.D.</given-names></name><name><surname>Rebeles</surname><given-names>J.</given-names></name><name><surname>Karlsson</surname><given-names>E.A.</given-names></name><name><surname>Schultz-Cherry</surname><given-names>S.</given-names></name><name><surname>Noah</surname><given-names>T.L.</given-names></name></person-group><article-title>Increased risk of influenza among vaccinated adults who are obese</article-title><source>Int J Obes</source><volume>41</volume><year>2017</year><fpage>1324</fpage><lpage>1330</lpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>D.H.</given-names></name><name><surname>Ravussin</surname><given-names>E.</given-names></name><name><surname>Heymsfield</surname><given-names>S.</given-names></name></person-group><article-title>COVID 19 and the patient with obesity - the editors speak out</article-title><source>Obesity</source><year>2020 Apr 1</year><pub-id pub-id-type="doi">10.1002/oby.22808</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Ilias</surname><given-names>I.</given-names></name><name><surname>Zabuliene</surname><given-names>L.</given-names></name></person-group><article-title>Hyperglycemia and the novel Covid-19 infection: possible pathophysiologic mechanisms</article-title><source>Med Hypotheses</source><volume>139</volume><year>2020</year><comment>109699</comment></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Yue</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name></person-group><article-title>Nucleocapsid protein of SARS-CoV activates interleukin-6 expression. through cellular transcription factor NF-κB</article-title><source>Virology</source><volume>365</volume><year>2007</year><fpage>324</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">17490702</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Kong</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>The membrane protein of SARS-CoV suppresses NF-kappaB activation</article-title><source>J Med Virol</source><volume>79</volume><year>2007</year><fpage>1431</fpage><lpage>1439</lpage><pub-id pub-id-type="pmid">17705188</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Canton</surname><given-names>J.</given-names></name><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R.</given-names></name><name><surname>Gutierrez-Alvarez</surname><given-names>F.J.</given-names></name><name><surname>Sanchez-Aparicio</surname><given-names>M.T.</given-names></name><name><surname>García-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>MERS-CoV 4b protein interferes with the NF-κB-dependent innate immune response during infection</article-title><source>PLoS Pathog</source><volume>14</volume><year>2018</year><comment>e1006838</comment></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Ulhaq</surname><given-names>Z.S.</given-names></name><name><surname>Soraya</surname><given-names>G.V.</given-names></name></person-group><article-title>Interleukin-6 as a potential biomarker of COVID-19 progression</article-title><source>Med Maladies Infect</source><year>2020 Apr 4</year><pub-id pub-id-type="doi">10.1016/j.medmal.2020.04.002</pub-id><comment>pii: S0399-077X(20)30088-3</comment></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Divella</surname><given-names>R.</given-names></name><name><surname>De Luca</surname><given-names>R.</given-names></name><name><surname>Abbate</surname><given-names>I.</given-names></name><name><surname>Naglieri</surname><given-names>E.</given-names></name><name><surname>Daniele</surname><given-names>A.</given-names></name></person-group><article-title>Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation</article-title><source>J Canc</source><volume>7</volume><year>2016</year><fpage>2346</fpage><lpage>2359</lpage></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Michalakis</surname><given-names>K.</given-names></name><name><surname>Venihaki</surname><given-names>M.</given-names></name><name><surname>Mantzoros</surname><given-names>C.</given-names></name><name><surname>Vazaiou</surname><given-names>A.</given-names></name><name><surname>Ilias</surname><given-names>I.</given-names></name><name><surname>Gryparis</surname><given-names>A.</given-names></name></person-group><article-title>In prostate cancer, low adiponectin levels are not associated with insulin resistance</article-title><source>Eur J Clin Invest</source><volume>45</volume><year>2015</year><fpage>572</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">25833038</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Ellulu</surname><given-names>M.S.</given-names></name><name><surname>Patimah</surname><given-names>I.</given-names></name><name><surname>Khaza'ai</surname><given-names>H.</given-names></name><name><surname>Rahmat</surname><given-names>A.</given-names></name><name><surname>Abed</surname><given-names>Y.</given-names></name></person-group><article-title>Obesity and inflammation: the linking mechanism and the complications</article-title><source>Arch Med Sci</source><volume>13</volume><year>2017</year><fpage>851</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">28721154</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>T.W.</given-names></name><name><surname>McPherson</surname><given-names>M.</given-names></name><name><surname>Gail Darlington</surname><given-names>L.</given-names></name></person-group><article-title>Obesity and cancer: existing and new hypotheses for a causal connection</article-title><source>EBioMedicine</source><volume>30</volume><year>2018</year><fpage>14</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">29526577</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A.J.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Lau</surname><given-names>C.C.</given-names></name><name><surname>Poon</surname><given-names>V.K.</given-names></name><name><surname>Chan</surname><given-names>C.C.</given-names></name></person-group><article-title>Leptin mediates the pathogenesisiof severe 2009 pandemic influenza A (H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity</article-title><source>J Infect Dis</source><volume>207</volume><year>2013</year><fpage>1270</fpage><lpage>1280</lpage><pub-id pub-id-type="pmid">23325916</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Lelis</surname><given-names>D.F.</given-names></name><name><surname>Freitas</surname><given-names>D.F.</given-names></name><name><surname>Machado</surname><given-names>A.S.</given-names></name><name><surname>Crespo</surname><given-names>T.S.</given-names></name><name><surname>Santos</surname><given-names>S.H.S.</given-names></name></person-group><article-title>Angiotensin-(1-7), adipokines and inflammation</article-title><source>Metabolism</source><volume>95</volume><year>2019</year><fpage>36</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">30905634</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Danser</surname><given-names>A.H.J.</given-names></name><name><surname>Epstein</surname><given-names>M.</given-names></name><name><surname>Batlle</surname><given-names>D.</given-names></name></person-group><article-title>Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is No evidence to abandon renin-angiotensin system blockers</article-title><source>Hypertension</source><year>2020</year><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.15082</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000641 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000641 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |